Mer­ck, Pfiz­er end patent feud over pneu­mo­coc­cal vac­cines with roy­al­ty-cen­tered set­tle­ment

A long-run­ning patent bat­tle be­tween two phar­ma gi­ants over their com­pet­ing pneu­mo­coc­cal con­ju­gate vac­cines has come to an end.

Mer­ck and Pfiz­er have reached a set­tle­ment agree­ment to dis­miss patent claims for all their PCV prod­ucts, Mer­ck an­nounced Thurs­day. It’s a deal that comes just a few months af­ter both com­pa­nies net­ted ap­provals for new vac­cines, with Pfiz­er get­ting the rub­ber stamp for its 20-va­lent shot in June and Mer­ck win­ning the green light for a 15-va­lent vac­cine in Ju­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.